EX-99.1 2 qsi-08072024xex991.htm EX-99.1 Document

Exhibit 99.1
qsi_logoxwordmarkxbluexrgb.jpg

Quantum-Si Reports Second Quarter 2024 Financial Results
Announces Release of Version 3 Sequencing Kit
Announces Two Additional Kit Launches Expected by End of 2024
BRANFORD, Conn. -- (BUSINESS WIRE) -- August 7, 2024 -- Quantum-Si Incorporated (Nasdaq: QSI) (“Quantum-Si,” “QSI” or the “Company”), The Protein Sequencing Company™, today announced financial results for the second quarter ended June 30, 2024.
Press Release Highlights
•Reported revenue of $622,000 in the second quarter of 2024
•Completed the first quarter of full commercial launch of the Platinum® instrument in Q2 2024
•Announces the launch of the version 3 sequencing kit
•Announced appointment of Chuck Kummeth as independent Chairman of the Board of Directors
•Expect to launch a version 2 library prep kit and a barcoding application specific library prep kit by the end of 2024
“I’m pleased with the progress that we made on the commercial ramp up of Platinum during the second quarter. We are seeing strong customer interest in the unique capabilities of Platinum, which was underscored by presentations at major scientific conferences over the last few months, including the American Society of Mass Spectrometry and the European Society for Human Genetics,” said Jeff Hawkins, President and Chief Executive Officer of Quantum-Si. “We are in the early stages of penetrating a large market opportunity in proteomics, as researchers seek a deeper understanding of the importance of protein sequences and identify high value applications of the technology.”

Hawkins continued, “Today, we also announce the launch of our version 3 sequencing kit. This new kit will continue to give customers deeper insights into an ever-expanding number of proteins, more peptides per protein and more amino acids per peptide. We remain laser-focused on delivering a compelling technology roadmap of enhancements to our hardware, software and chemistries and now expect to release a version 2 of our library prep kit as well as a barcoding application specific library prep kit by the end of 2024. We believe these innovations will continue to extend our leadership in protein sequencing. Finally, we added Chuck Kummeth as independent Chairman of our Board of Directors. We look forward to benefitting from the experience Chuck has gained through decades of leadership with leading life sciences tools companies like Bio-Techne and Thermo Fisher Scientific.”
Second Quarter 2024 Financial Results

For the second quarter of 2024, the Company recorded revenue of $622,000. Gross profit was $354,000 and gross margin was 57%. For the six months ended June 30, 2024, the Company recorded revenue of $1.1 million, gross profit of $623,000, and gross margin of 57%. The periodic gross margin rate is expected to be variable in the near term as the Company works through the initial stages of commercialization as well as the timing and mix of product sales between instruments and consumable kits.

Total operating expenses were $26.8 million in the second quarter of 2024, compared to $27.0 million for the same period in the prior year, and $50.4 million for the six months ended June 30, 2024, compared to $56.3 million for the same period in the prior year. Adjusted total operating expenses were $24.4 million in the


second quarter of June 30, 2024, compared to $24.0 million for the same period in the prior year, and adjusted total operating expenses for the six months ended June 30, 2024 was $46.3 million compared to $48.7 million for the same period in the prior year. Driven by the Company’s 2023 initiative to enact operating changes to utilize capital in the most efficient manner while accelerating R&D innovation and delivering product enhancements to customers, the overall adjusted operating expenses included reductions in R&D and G&A spend, partially offset with increased spending for commercial operations. Overall, the Company has been able to reduce core areas of spend while accelerating R&D focus, efficiency, and delivery while still funding the Company’s full commercial launch of its Platinum® instrument.
Net loss was $23.1 million in the second quarter of 2024, compared to a net loss of $25.6 million in the same period of the prior year, and a net loss of $42.6 million for the six months ended June 30, 2024, compared to a net loss of $49.2 million for the same period in the prior year. Adjusted EBITDA was negative $22.6 million in the second quarter of 2024, compared to negative $22.9 million in the same period of the prior year, and negative $43.2 million for the six months ended June 30, 2024, compared to negative $46.6 million for the same period in the prior year. A reconciliation of the non-GAAP financial measures adjusted total operating expenses and adjusted EBITDA is provided in a table included in this press release.
As of June 30, 2024, the Company’s cash and cash equivalents and investments in marketable securities were $218.1 million.
2024 Financial Guidance
The Company reaffirms its full year 2024 financial guidance as follows:
Revenue$3.7 - $4.2 million
Adjusted total operating expensesLess than $103 million
Total cash usageLess than $100 million
The Company also maintains the expectation that the balance in cash and cash equivalents and investments in marketable securities of $218.1 million as of June 30, 2024 will provide a runway into 2026.
Webcast and Conference Call Information
Quantum-Si will host a conference call to discuss its second quarter 2024 financial results on Wednesday, August 7, 2024, at 4:30 p.m. Eastern Time. Individuals interested in listening to the conference call may do so by joining the live webcast in the Investors section of the Quantum-Si website under Events & Presentations. Alternatively, individuals can register here to receive a dial-in number and personalized PIN to participate in the call. An archived webcast of the event will be available for replay following the event.
About Quantum-Si Incorporated
Quantum-Si, The Protein Sequencing Company™, is focused on revolutionizing the growing field of proteomics. The Company’s suite of technologies is powered by a first-of-its-kind semiconductor chip designed to enable next-generation single-molecule protein sequencing and digitize proteomic research in order to advance drug discovery and diagnostics beyond what has been possible with DNA sequencing. Learn more at quantum-si.com or follow us on LinkedIn or X.
Use of Non-GAAP Financial Measures
This press release presents the non-GAAP financial measures “adjusted total operating expenses” and “adjusted EBITDA.” The most directly comparable measures for these non-GAAP financial measures are total operating expenses and net loss. The Company has included below adjusted total operating expenses, which presents the Company’s total operating expenses after excluding goodwill impairment, stock-based compensation and restructuring costs. In addition, adjusted EBITDA further excludes interest, taxes, depreciation, amortization,
2

dividend income, unrealized and realized gains and losses on marketable securities, changes in fair value of warrant liabilities and other income or expense.
A discussion of the reasons why management believes that the presentation of non-GAAP financial measures provides useful information to investors regarding the Company’s financial condition and results of operations is included as Exhibit 99.2 to the Company’s Current Report on Form 8-K filed with the Securities and Exchange Commission (the “SEC”) on August 7, 2024.
Forward Looking Statements
This press release includes “forward-looking statements” within the meaning of the “safe harbor” provisions of the United States Private Securities Litigation Reform Act of 1995. The actual results of the Company may differ from its expectations, estimates, and projections and, consequently, you should not rely on these forward-looking statements as predictions of future events. Words such as “expect,” “estimate,” “project,” “budget,” “forecast,” “anticipate,” “intend,” “plan,” “may,” “will,” “could,” “should,” “believes,” “predicts,” “potential,” “continue,” and similar expressions (or the negative versions of such words or expressions) are intended to identify such forward-looking statements. These forward-looking statements include, without limitation, the Company’s expectations with respect to future performance and development and commercialization of products and services, its anticipated cash runway and its financial guidance for the full year 2024. These forward-looking statements involve significant risks and uncertainties that could cause the actual results to differ materially from those discussed in the forward-looking statements. Most of these factors are outside the Company’s control and are difficult to predict. Factors that may cause such differences include, but are not limited to: the inability to maintain the listing of the Company’s Class A common stock on The Nasdaq Stock Market; the ability of the Company to grow and manage growth profitably and retain its key employees; the Company’s ongoing leadership transitions; changes in applicable laws or regulations; the ability of the Company to raise financing in the future; the success, cost and timing of the Company’s product development and commercialization activities; the commercialization and adoption of the Company’s existing products and the success of any product the Company may offer in the future; the potential attributes and benefits of the Company’s commercialized Platinum® protein sequencing instrument and kits and the Company’s other products once commercialized; the Company’s ability to obtain and maintain regulatory approval for its products, and any related restrictions and limitations of any approved product; the Company’s ability to identify, in-license or acquire additional technology; the Company’s ability to maintain its existing lease, license, manufacture and supply agreements; the Company’s ability to compete with other companies currently marketing or engaged in the development or commercialization of products and services that serve customers engaged in proteomic analysis, many of which have greater financial and marketing resources than the Company; the size and growth potential of the markets for the Company’s products and services, and its ability to serve those markets once commercialized, either alone or in partnership with others; the Company’s estimates regarding future expenses, future revenue, capital requirements and needs for additional financing; the Company’s financial performance; and other risks and uncertainties described under “Risk Factors” in the Company’s most recent Annual Report on Form 10-K and Quarterly Reports on Form 10-Q and in the Company’s other filings with the SEC. The Company cautions that the foregoing list of factors is not exclusive. The Company cautions readers not to place undue reliance upon any forward-looking statements, which speak only as of the date made. The Company does not undertake or accept any obligation or undertaking to release publicly any updates or revisions to any forward-looking statements to reflect any change in its expectations or any change in events, conditions, or circumstances on which any such statement is based.
3

QUANTUM-SI INCORPORATED
CONDENSED CONSOLIDATED BALANCE SHEETS
(in thousands, except share and par value amounts)
(unaudited)
June 30,
2024		December 31,
2023
Assets
Current assets:
Cash and cash equivalents$59,552 $133,860 
Marketable securities158,565 123,876 
Accounts receivable, net of allowance of $0 and $0, respectively 598 368 
Inventory4,854 3,945 
Prepaid expenses and other current assets2,901 4,261 
Total current assets226,470 266,310 
Property and equipment, net16,211 16,275 
Internally developed software, net124 532 
Operating lease right-of-use assets13,248 14,438 
Other assets695 695 
Total assets$256,748 $298,250 
Liabilities and stockholders’ equity
Current liabilities:
Accounts payable$1,379 $1,766 
Accrued payroll and payroll-related costs2,883 4,943 
Accrued contracted services1,645 1,519 
Accrued expenses and other current liabilities3,446 1,815 
Current portion of operating lease liabilities
1,655 1,566 
Total current liabilities11,008 11,609 
Warrant liabilities478 1,274 
Operating lease liabilities11,991 13,737 
Other long-term liabilities
11 11 
Total liabilities23,488 26,631 
Stockholders’ equity
Class A Common stock, $0.0001 par value; 600,000,000 shares authorized as of June 30, 2024 and December 31, 2023; 122,382,332 and 121,832,417 shares issued and outstanding as of June 30, 2024 and December 31, 2023, respectively12 12 
Class B Common stock, $0.0001 par value; 27,000,000 shares authorized as of June 30, 2024 and December 31, 2023; 19,937,500 shares issued and outstanding as of June 30, 2024 and December 31, 20232 2 
Additional paid-in capital771,460 767,239 
Accumulated other comprehensive loss(7)- 
Accumulated deficit(538,207)(495,634)
Total stockholders’ equity
233,260 271,619 
Total liabilities and stockholders’ equity
$256,748 $298,250 
4

QUANTUM-SI INCORPORATED
CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE LOSS
(in thousands, except per share amounts)
(unaudited)
Three months ended June 30,Six months ended June 30,
2024202320242023
Revenue:
Product$584 $187 $1,012 $438 
Service38 18 67 21 
Total revenue622 205 1,079 459 
Cost of revenue268 127 456 257 
Gross profit354 78 623 202 
Operating expenses:
Research and development14,381 15,834 26,482 34,001 
Selling, general and administrative12,424 11,136 23,952 22,314 
Total operating expenses26,805 26,970 50,434 56,315 
Loss from operations(26,451)(26,892)(49,811)(56,113)
Dividend and interest income2,887 2,483 6,461 4,702 
(Loss) gain on marketable securities, net— (1,181)— 1,761 
Change in fair value of warrant liabilities477 (310)796 81 
Other (expense) income, net(12)327 (19)385 
Loss before provision for income taxes(23,099)(25,573)(42,573)(49,184)
Provision for income taxes— — — — 
Net loss$(23,099)$(25,573)$(42,573)$(49,184)
Net loss per common share attributable to common stockholders, basic and diluted$(0.16)$(0.18)$(0.30)$(0.35)
Weighted-average shares used to compute net loss per share attributable to common stockholders, basic and diluted141,939141,507141,856140,897
Other comprehensive gain (loss):
Net unrealized gain on marketable securities, net of tax$28 $— $— $— 
Foreign currency translation adjustment(2)— (7)— 
Total other comprehensive gain (loss), net of tax26 — (7)— 
Comprehensive loss$(23,073)$(25,573)$(42,580)$(49,184)
5

QUANTUM-SI INCORPORATED
RECONCILIATION OF U.S. GAAP TO NON-GAAP FINANCIAL MEASURES
(in thousands)
(unaudited)

Three months ended June 30,Six months ended June 30,
2024202320242023
Net loss$(23,099)$(25,573)$(42,573)$(49,184)
Adjustments to reconcile to EBITDA:
Dividend and interest income(2,887)(2,483)(6,461)(4,702)
Depreciation and amortization1,387 1,090 2,448 1,893 
EBITDA(24,599)(26,966)(46,586)(51,993)
Adjustments to reconcile to Adjusted EBITDA:
Loss (gain) on marketable securities, net— 1,181 — (1,761)
Change in fair value of warrant liabilities(477)310 (796)(81)
Other expense (income), net12 (327)19 (385)
Stock-based compensation2,400 1,865 4,009 5,773 
Restructuring costs31 1,067 174 1,880 
Adjusted EBITDA$(22,633)$(22,870)$(43,180)$(46,567)

Three months ended June 30,Six months ended June 30,
2024202320242023
Total operating expenses$26,805 $26,970 $50,434 $56,315 
Adjustments to reconcile to Adjusted total operating expenses:
Stock-based compensation(2,400)(1,865)(4,009)(5,773)
Restructuring costs(31)(1,067)(174)(1,880)
Adjusted total operating expenses$24,374 $24,038 $46,251 $48,662 

Investor Contact:
Doug Farrell
VP, Investor Relations
ir@quantum-si.com
Media Contact:
Katherine Atkinson
SVP, Commercial Marketing
media@quantum-si.com
Source: Quantum-Si Incorporated
6